This compound serves as a crucial intermediate in medicinal chemistry, particularly in the synthesis of Ticagrelor, an antiplatelet drug used for treating acute coronary syndromes and preventing thrombotic events. The trans-2-(2,5-difluorophenyl)cyclopropyl structure, protected by a tert-butyl carbamate group, provides enhanced metabolic stability and facilitates binding to the P2Y12 receptor on platelets. Its unique chemical features make it valuable for drug discovery in cardiovascular therapeutics, enabling the development of potent and selective inhibitors to improve patient outcomes in antithrombotic therapy.